Back to Aculeus

Aculeus appoints leading preclinical expert as Strategic Safety and Toxicology advisor

July 11, 2022

MELBOURNE (July 12, 2022) – Aculeus Therapeutics (“Aculeus”) is excited to announce the appointment of Dr Gerald (Jerry) Fisher to Aculeus’ Scientific Advisory Group.

Dr Fisher is a highly experienced drug safety, toxicological sciences and metabolism expert. Formerly Senior Vice President of Drug Safety and Metabolism at Wyeth-Ayerst Research, Jerry was responsible for preclinical safety across all of Wyeth including pharma, animal health and OTC and managed 600 people at 6 sites in the US and Europe. Prior to Wyeth, Jerry was VP of Drug Safety and Metabolism at Sandoz Research Institute.

Jerry has been involved in well over 100 IND applications and brings this deep expertise to Aculeus at an exciting time in the progression of it’s STING program.

Aculeus CEO Mark Devlin said, “It’s fantastic to have Jerry as part of the Aculeus scientific advisory team and the company is already benefiting from Jerry’s expertise as our STING program continues to progress though late preclinical assessments.”


About Aculeus Therapeutics


Aculeus Therapeutics is a Biotech company based in Melbourne Australia, developing small molecule drugs that modulate the immune system for the treatment of cancer and other serious diseases. Aculeus is doing this by developing drugs that target the Stimulator of Interferon Genes (STING) biochemical pathway.

Aculeus in-licensed its lead programs, STING and ENPP1, in 2020 from the CRC for Cancer Therapeutics, a Public Private Partnership between a number of Australia’s leading Medical Research Institutes, Universities and Industry partners with a track record of scientific and commercial success. Aculeus is currently advancing it’s STING agonist program through preclinical studies in preparation for formal IND-enabling studies commencing in 2022.


For more information, visit or connect with us on Twitter @AculeusTx.

Back to news